Provista Diagnostics’ Blood-based Diagnostic Featured in Oncology & Hematology Review

Highlights the Potential of Serum Protein Biomarkers in Conjunction with Tumor Associated Autoantibodies to Improve Early Detection of Breast Cancer in conjunction with standard imaging practices

New York, NY – December 5, 2014 – Provista Diagnostics, Inc., a privately-held molecular diagnostics company focused on developing and commercializing a new generation of proprietary blood-based diagnostic, prognostic and monitoring tests designed to address the unmet needs in women’s cancer, such as breast and gynecologic cancers, today announced that its blood-based diagnostic for the early detection of breast cancer was featured in the 2014 Fall edition of Oncology & Hematology Review in an article titled, “Potential Use of Biomarkers to Augment Clinical Decisions for the Early Detection of Breast Cancer.”

The review highlighted advances in serum protein biomarkers (SPB), tumor-associated autoantibodies (TAAbs) and biomarkers used in breast cancer detection to provide a perspective on how these technologies may provide clinical benefit when combined with current imaging modalities.

In summary, “ongoing development has resulted in a test that is highly promising in the ability to detect breast cancer in a broader population of women in conjunction with standard imaging practices.”

“We are especially pleased to have our proprietary technology featured in this comprehensive analysis in Oncology and Hematology Review. The article highlights the clinical benefits of combining the best available technologies to provide women with more a precise and earlier detection of breast cancer,” said David Reese, PhD, President and CEO of Provista. “We believe our proteomics approach, which combines the specificity of tumor associated autoantibodies with the sensitivity of known serum protein biomarkers along with standard-of-care imaging, will ultimately provide a more precise identification of deadly breast cancers in women.”

Provista Diagnostics is currently conducting multiple prospective trials to establish the combined role of SPBs and TAAbs to differentiate benign from invasive breast cancers in woman 25 to 75 years old. 

About Breast Cancer

Breast cancer is the most common malignant disease in women: according to US statistics, one in 8 women will be diagnosed with breast cancer in her lifetime. According to the American Cancer Society, nearly 233,000 women will be diagnosed with breast cancer in the U.S. in 2014. Approximately 40,000 deaths occur from breast cancer each year. While biomarkers are often used to augment detection of various cancers, definitive biomarkers for breast cancer have remained elusive.

About Provista

Provista Diagnostics is a privately held molecular diagnostics company focused on developing and commercializing a new generation of proprietary blood-based proteomic diagnostic, prognostic and monitoring tests designed to address the unmet needs in women’s cancer, such as breast and gynecologic cancers. Provista Diagnostics’ state-of-the-art, high-complexity clinical laboratory is accredited by the College of American Pathologists (CAP) and with the Clinical Laboratory Improvement Amendments (CLIA).

Additional information about Provista Diagnostics is available at ProvistaDx.com

Information about Provista Diagnostics’ clinical trials is available at ClinicalTrials.gov

Safe Harbor Statement

Statements contained in this communication not relating to historical facts are forward-looking statements that are intended to fall within the safe harbor rule for such statements under the Private Securities Litigation Reform Act of 1995. The information contained in the forward-looking statements is inherently uncertain, and Provista’s actual results may differ materially due to a number of factors, many of which are beyond Provista’s ability to predict or control, including among others, viability and effectiveness of our sales approach and overall marketing strategies, the outcome of development or regulatory review of our products, commercial success or acceptance by the medical community, competitive responses, our ability to raise additional capital, and the ability to successfully file a registration statement with the SEC. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from the forward-looking statements. Provista operates in a highly competitive and rapidly changing business and regulatory environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. Except as is expressly required by the federal securities laws, Provista undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason.

###